Kornimate/medical-research-clean huggingface dataset:
a cross-sectional survey of colorectal cancer patients in different age groups

Conditions: Colorectal Cancer; Age Problem

Summary: this study will help to determine the main clinical symptom differences between patients of different ages, discover the family genetic predisposition of patients of different ages, and obtain the differences in pathological characteristics of patients of different ages, so as to provide help and basis for more accurate and earlier prevention and treatment of colorectal cancer.

colorectal cancer is one of the common and highly prevalent malignant tumors of the gastrointestinal system. previous studies have found that there may be some differences in disease characteristics and prognosis of colorectal cancer patients at different ages, such as patients with early-onset colorectal cancer (age \<50 years) tend to have a worse prognosis than patients with late-onset colorectal cancer (age ≥50 years). however, existing studies on the characteristics of colorectal cancer patients at different ages are not well studied to answer the differences between these patients and develop targeted diagnostic and treatment strategies. cross-sectional survey research, which uses survey research to collect data on a characteristic group over a certain period of time and statistically analyzes the data to obtain the characteristics of a certain disease or a certain treatment strategy, is a more mature approach that is particularly suitable for the questions that need to be answered in this study. investigators found that no similar studies have been registered and conducted by searching the official websites of the china clinical research registry and clinical trial, and there is a lack of research data on the chinese population. therefore, investigators believe there is an urgent need for a cross-sectional survey to study the symptomatic characteristics, family history, and pathologic features of colorectal cancer patients. this study will help to determine the main clinical symptom differences between patients of different ages, discover the family genetic predisposition of patients of different ages, and obtain the differences in pathological characteristics of patients of different ages, so as to provide help and basis for more accurate and earlier prevention and treatment of colorectal cancer.

Eligibility criteria:
inclusion criteria: 1. adults aged 18 years and older with a pathologic diagnosis of colorectal cancer; 2. undergoing surgical treatment of the primary lesion; 3. voluntary participation of patients. exclusion criteria: 1. do not agree to participate in the survey or withdraw informed consent 2. patients did not receive surgical treatment or did not undergo pathologic examination

Keywords: colorectal caner age group family history symptomatic characteristics pathologic features
impact of oral glucose tolerance test on extent of hemoglobin glycation

Conditions: Blood Glucose, High; Oral Hypoglycaemic Overdose

Summary: the glycation extent of human hemoglobin is under control of the maillard reaction, a chemical interaction between an amino acide and a reducing sugar. about 5% ( 31.1 mmol/mol) of hemoglobin molecules secluded in a red blood cell are glycated; excessive values \> 6.5% point to prediabetes or overt diabetes mellitus. to ascertain the diagnosis doctors prescribe oral glucose tolerance upon which glucose concentrations in blood increase - how much hba1c reacts under these circumstances is ill known.

medical laboratory assays for delineation of impaired glucose metabolism and overt diabetes mellitus, beyond measurement of (fasting) blood serum or plasma glucose levels, include extent of hemoglobin a1c glycation, concentration of fructosamines, insulin concentrations to calculate the homeostasis model assessment (homa) index and other clinically putative biomarkers of glucose homoeostasis. hba1c levels form now part of routine elucidation of metabolic disorders and are used for therapy monitoring. initially used to monitor glucose levels in follow-up care of diabetics it is considered as a track marker of ups and downs of blood glucose concentrations. its behavior under the 2 h period of oral glucose tolerance tests (ogtt) is ill known - most clinicians believe the glycation extent will not change. since the dynamics of glycation is temperature dependent,non-febrile patients under ogtt likely keep their glycation extent between time zero and 120 min after glucose charge constant but this has not been investigated and with the sensitive lab assays for hba1c now in use we postulate a significant increase in glycation. the patient registry includes recruited children and adults sick from diabetes, overweight or metabolic syndrome as a whole. three medical offices will address their patients to the vidymed lab to perform the ogtt framed by lab assays on venous blood samples

Eligibility criteria:
inclusion criteria: * apparently healthy subjects or subjects supposedly experiencing a metabolic disease (e.g. prediabetes) subjects with asked for fasting blood glucose exclusion criteria: * current steroid use thyroid dysfunction (free-thyroxin levels \ 19 pmol/l, hscrp \> 10 mg/l hospitalized

Keywords: glucose, insulin, hba1c
a study of bgb-11417 in participants with myeloid malignancies

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasm

Summary: the study will determine the safety, tolerability, recommended phase 2 dose (rp2d) and preliminary efficacy of bgb-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (aml) and myelodysplastic syndrome (mds)or mds/myeloproliferative neoplasm (mpn) .


Eligibility criteria:
key inclusion criteria: 1. confirmed diagnosis of one of the following by 2016 world health organization criteria: * aml, nonacute promyelocytic leukemia * mds * mds/mpn 2. eastern cooperative oncology group performance status of 0 to 2. 3. adequate organ function defined as: * creatinine clearance ≥ 50 milliliters/minute (ml/min) (or between 30 and 49 ml/min in unfit aml cohort) * adequate liver function 4. life expectancy of \> 12 weeks. 5. ability to comply with the requirements of the study. key exclusion criteria: 1. a diagnosis of acute promyelocytic leukemia. 2. history of prior malignancy, with the exception of either a history of mds or mds/mpn that has transformed to aml, or other prior malignancy that was treated with a full curative intent and no evidence of recurrence within the past 2 years (eg, localized skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized gleason score ≤ 6 prostate cancer) 3. antecedent mpn including myelofibrosis, essential thrombocytosis, polycythemia vera, or chronic myelogenous leukemia with or without bcr-abl1 translocation and aml with bcr-abl1 translocation. 4. prior therapy with a b-cell lymphoma-2 inhibitor 5. known central nervous system involvement by leukemia. note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: bgb-11417 azacitidine posaconazole aml mds mds/mpn
the analgesic efficacy of vitamin b complex in critically ill obstetrics after caesarean section

Conditions: Analgesia; Post Operative Pain; Cesarean Section

Summary: we aim to investigate the value of vitamin b (b1, b6, b9, b12) on post-cesarean section analgesia in addition to the standard opioid-sparing multimodal regimen to achieve more robust analgesia with minimal side effects.

optimum analgesia is an essential component in enhanced recovery after elective and emergency caesarean section. opioid-based analgesia negatively affects maternal functional recovery. unlike other types of surgeries, the performance and the quality of postoperative recovery in caesarean section affects two individuals: the patient and their infant, hence it is recommended to use opioid-sparing medications post-caesarean section. multimodal analgesia is recommended for post-caesarean section pain control. the main properties of its components are to promote return of (i) mobility (ii) oral intake (iii) normal bowel function (iv) micturition: trial without urinary catheter (v) activities of daily living, with few adverse effects: inactive metabolites (no nausea, vomiting, sedation, pruritus, constipation or respiratory depression), readily available after discharge home, little risk of dependency (especially long-term opioids), minimal risk of hyperalgesia or chronic pain and cost-efficient with minimally invasive technique and no side-effects on the neonate. the morbidity of critically ill obstetrics can increase due to inadequate control of pain and also due to the consumption of opioid analgesia due to associated respiratory depression, sedation, and nausea. multimodal analgesia is strongly recommended. an immune-histochemistry study found that b vitamins potentiate acute morphine antinociception. in other studies, the value of vitamin b complex on postoperative analgesia was discussed and investigated in different combinations another study reported the value of folic acid in decreasing gastric hypersensitivity in maternal stress in rats. other studies explained the benefit of folic acid in analgesia through modulating gut microbiota, reducing inflammation, modulating purinergic signaling, and promoting nerve repair (6)this is the first study to investigate the effect of vitamin b9 (folic acid ) and other vitamin b (b1, b6, b12) beside the standard opioid sparing analgesics on post-caesarean section pain in critically ill obstetrics.

Eligibility criteria:
inclusion criteria: * critically ill -obstetric patients who will be delivered by cesarean section under neuraxial anesthesia. exclusion criteria: 1. patient's refusal to participate 2. known allergy to one or more of the given components. 3. disturbed conscious level. 4. prolonged or complicated surgery; defined by operative time of more than 90 min. 5. severe liver dysfunction or failure 6. severe renal dysfunction or failure. 7. severe thrombocytopenia; platelets less than 50
an observational study on metabolic syndrome parameters in schizophrenia patients treated with atypical antipsychotics

Conditions: Schizophrenia; Metabolic Syndrome X

Summary: the purpose of the study is to find and follow-up the metabolic syndrome parameters on patients administering atypical antipsychotics.

sampling method details: group of patients using the same atypical anti-psychotic.

Eligibility criteria:
inclusion criteria: * female and male patients diagnosed as schizophrenia by the diagnostic and statistical manual of mental disorders. * age between 18-45 years * patients who started atypical antipsychotic drug treatment or patients who switched from the previous conventional or atypical antipsychotic treatment to another atypical antipsychotic drug treatment by the decision of their physicians. exclusion criteria: * patients who are pregnant or considering pregnancy.

Keywords: atypical antipsychotics metabolic syndrome safety
validation of a prediction score for recurrent c. difficile infection: implementation for treatment algorithm strategies

Conditions: Clostridium Difficile Infection

Summary: the objective of the present study is to derive a high-risk r-icd prediction rule and a prospective implementation of this prediction rule.

for objectives 1 and 2, a retrospective study of the microbiology database will be carried out and the medical records will be consulted to collect the variables included in annex 2. the other prediction rules to be compared are those of cobo et al., reigadas et al and gerding et al. we will review a total of 215 patients according to the calculation of the sample size (see section) a prospective study will also be carried out in which the positive patients for c. difficile determined by the microbiology service of the general university hospital gregorio marañón will be included. the medical records of the selected cases will be reviewed. all patients included in the prospective study (objective 3) will receive the information sheet and consent sheet that they must sign for this study (annex 1). these patients will be followed and the variables included in annex 2 will be collected.

Eligibility criteria:
inclusion criteria: * for the retrospective cohort, those patients with a positive sample for icd will be randomly selected from the microbiology database. * for the prospective cohort: after the routine identification of a case of dci by the microbiology laboratory, those new cases will be included in the study. exclusion criteria: * children under 18 years or patients with \<3 faeces not trained in the last 24 hours will not be included.
switch to bictegravir/emtricitabine/tenofovir alafenamide after renal transplant

Conditions: HIV Infections; Renal Transplant Rejection

Summary: this is an open-label study, where participants will be switched from their current hiv medication to the study drug, biktarvy. open-label means both the investigator and the participant will know what drug will be given. participants will be followed for 48 weeks in order to monitor the efficacy, safety and tolerability of biktarvy. the investigator hypothesizes that biktarvy will be an important addition to the management of hiv-positive post renal transplant patients, especially since it is a one pill daily dosing regimen, thereby decreasing the pill burden in this population.


Eligibility criteria:
inclusion criteria: * at least 18 years old on day of signing informed consent * positive for human immunodeficiency virus (hiv) * received a previous renal transplant * must have controlled hiv infection for at least 3 months prior to enrollment exclusion criteria: * received a kidney from a donor who was hiv positive (unless a false positive) * currently taking biktarvy for treatment of hiv * has allergies to any of the hiv medications in biktarvy (bictegravir, emtricitabine, or tenofovir alafenamide) * currently taking dofetilide or rifampin * is pregnant or breastfeeding

Keywords: hiv positive post renal transplant bictegravir/emtricitabine/tenofovir alafenamide antiretroviral biktarvy
pilot study of combination therapy with chop-zenapax (chop-daclizumab)

Conditions: HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL)

Summary: the purpose of this study is to determine the safety of the combination of chop plus daclizumab in patients with atll previously untreated with anthracycline based chemotherapy.


Eligibility criteria:
inclusion criteria: 1. histologically confirmed atll requiring treatment 1. frank acute leukaemia or lymphoma subtypes 2. chronic and smouldering cases should be considered if they are symptomatic and require therapy, or there is evidence of disease progression 2. no previous treatment with anthracycline based cytotoxic chemotherapy a. patients may have received interferon and /or zidovudine and/or non-anthracycline based therapy 3. age 18-75 years 4. written informed consent exclusion criteria: 1. hiv 1 or 2 positivity 2. pregnancy or breast-feeding 3. concomitant chemo-radiotherapy 4. prior hepatic or renal insufficiency with a bilirubin or transaminases greater than 5 times the normal range or a creatinine greater than 150μmol/l (not related to hypercalcaemia) following rehydration 5. other concomitant neoplasms not related to htlv-i 6. cardiac or respiratory insufficiency with an ecog score of greater than 3 7. any serious active uncontrolled infection
f 18 t807 tau pet imaging in familial amyotrophic lateral sclerosis

Conditions: Amyotrophic Lateral Sclerosis (ALS)

Summary: the purpose of this research study is to evaluate tau distribution in the brain of subjects with: als caused by different genetic mutations, any mutation carriers (with or without symptoms), any non-mutation carrier, any sporadic ftd, normal controls.


Eligibility criteria:
inclusion criteria: 1. male or female participants, at least 18 years of age. 2. clinically diagnosed with amyotrophic lateral sclerosis (als), fronto-temporal dementia (ftd), or both; or a carrier of a mutation known to cause als or ftd (with or without symptoms); or a normal control. 3. participant is able and willing to undergo testing (psychometric testing, mri or ct, pet, radioactive tracer injection; for those unable to undergo an mri, ct will be used to generate regions-of-interest). 4. pre-menopausal women will undergo a urine pregnancy test within 24 hours of drug administration. exclusion criteria: 1. has any condition that, in the investigator's opinion, could increase risk to the participant, limit the participant's ability to tolerate the experimental procedures, or interfere with the collection/analysis of the data (for example, participants with significant respiratory involvement may not be able to lie flat during the scanning procedures). 2. is deemed likely unable to perform the imaging procedures for any reason. 3. has a high risk for torsades de pointes or is taking medications known to prolong qt interval. 4. has hypersensitivity to f 18 t807 or any of its excipients. 5. contraindications to pet, pet-ct or mr (e.g. electronic medical devices, inability to lie still for long periods) that make it unsafe for the individual to participate. 6. severe claustrophobia. 7. currently pregnant or breast-feeding.

Keywords: fronto-temporal dementia tauopathies nervous system diseases neurodegenerative diseases
duration of urinary catheter treatment after cesarean delivery under spinal anesthesia

Conditions: Urinary Retention; Cesarean Section Complications

Summary: in this study a total of 150 parturients undergoing cesarean delivery under spinal anesthesia will be randomized to have their urinary catheters kept in place for 8, 10 or 12 hours. the incidence of urinary retention and interventions needed for any potential urinary retention will be assessed.

in this study a total of 150 parturients undergoing cesarean delivery under spinal anesthesia will be randomized to have their urinary catheters kept in place for 8, 10 or 12 hours. the incidence of urinary retention and interventions needed for any potential urinary retention will be assessed.

Eligibility criteria:
inclusion criteria: * after informed consent, signed the participation form (volunteered for the study) * cesarean section * spinal anesthesia exclusion criteria: * prior neuraxial analgesia (epidural or spinal) for attempted labour
transpulmonary gradient after cardiac surgery under cardiopulmonary bypass

Conditions: Acute Respiratory Distress Syndrome After Cardiac Surgery Under Cardiopulmonary Bypass

Summary: get a better understanding of the pathophysiological processes of acute respiratory failure following cardiopulmonary bypass to initiate timely therapies targeted on a cell line. demonstrate that there is a relationship between increased transpulmonary gradients of inflammation biomarkers (srage, sicam-1, spb, pai-1, ros) and pulmonary vascular resistance on the one hand and alveolo-capillary gas exchange on the other hand after cardiac surgery under cardiopulmonary bypass.


Eligibility criteria:
inclusion criteria: * patient man or woman \> 18 y.o. * patient has signed informed consent prior to the study * patient affiliated to a social security administration * patient operated on for cardiac surgery at the university hospital of strasbourg. * patient at high risk for postoperative respiratory failure defined by a slip score (kor et al.) ≥ 22 kor: * high-risk cardiac intervention under cardiopulmonary bypass (19 pts) * copd (10 pts) * diabetes (6 pts) * gastroesophageal reflux (7 pts) * alcohol abuse (11 pts) * scheduled use of a pulmonary artery catheter and a left atrial catheter exclusion criteria: * inability to obtain informed consent from the patient and / or unable to give informed patient information (difficulty understanding ...) * urgent surgery (\<24h) * acute heart failure * patient ventilated preoperatively * allergy to latex * persons deprived of liberty or under judicial protection * patient placed under guardianship * pregnancy * breastfeeding
assessment of eloquent function in brain tumor patients

Conditions: Primary Brain Tumor; Metastatic Brain Tumor

Summary: purpose of the study: aim 1: prospectively collect pre-operative \[functional magnetic resonance imaging (fmri), diffusion tensor imaging (dti), magnetoencephalography (meg)\] and intra-operative mapping data in patients with intra-axial brain tumors to assess how well each modality predicts the location of eloquent brain function. in addition, each modality will be compared with the other. aim 2: assess reorganization of eloquent brain function and plasticity in patients with intra-axial brain tumors. this will be accomplished by prospectively collecting post-operative mapping studies and neuropsychological tests to compare them to prior mapping studies as stated above.

any patient with a primary or metastatic brain tumor in or near an eloquent area would be eligible for participation in the study assuming no contraindications to any of the studies or operative procedure. pre-operative evaluation will include clinical evaluation, neuropsychological testing, magnetic resonance imaging (mri) brain with and without contrast, fmri, dti tractograms, and meg studies as well as standard pre-operative work-up. intra-operative procedures include all non-invasive pre-operative mapping data being incorporated into the operative procedure with imaging tools that are routinely used during neurosurgical procedures. participants will have awake mapping performed. usual standards of care will be followed during craniotomy, mapping, and tumor resection or biopsy. post-operative procedures include routine post-operative care and assessment consisting of clinical examinations and imaging obtained within 24 hours post-resection. participants will have routine follow-up outpatient appointments after surgery which will include neurologic assessment and follow-up imaging (mri with and without contrast) for their tumors as appropriate. the experimental portion of the protocol is incorporating repeat neuropsychological testing and mapping studies (fmri, dti, meg) studies at 2 and 6 months post-surgery into their routine follow-up.

Eligibility criteria:
inclusion criteria: * 19 years and older * brain tumor in or near eloquent brain regions that is appropriate for attempted resection * appropriate body habitus and mental status/capacity to participate with non-invasive or invasive mapping * benign or malignant intra-axial brain tumor * primary or metastatic intra-axial brain tumor exclusion criteria: * any contraindication to mri (i.e. implanted devices) * inappropriate body habitus or mental status/capacity to participate with non-invasive or invasive mapping in a safe and reliable manner * declining to participate * lacks capacity to understand the study or consent for themselves * neurologic status which precludes testing (poor function- not testable) * positive pregnancy test * end stage renal disease or severe renal dysfunction

Keywords: brain mapping brain tumor